--- title: "Tirzepatide | PepTracker Pro" url: https://peptrackerpro.com/peptides/tirzepatide description: "A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Aliases Mounjaro +1 more Evidence High Evidence Last Updated 2026-06-30 Reading Time 4 min ## What It Is Tirzepatide is a first-in-class dual incretin agonist that activates both the GIP and GLP-1 receptors. FDA-approved under the brand names Mounjaro (diabetes) and Zepbound (weight management), it has demonstrated significant weight loss and glycemic control in clinical trials. In 2026, tirzepatide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2 or F3 — becoming the second FDA-approved pharmacotherapy for MASH after resmetirom (Rezdiffra). The SYNERGY-NASH Phase 2 trial showed 51.8%, 62.8%, and 73.3% of participants on 5 mg, 10 mg, and 15 mg doses achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 13.2% on placebo. Additionally, 59.1%, 53.3%, and 54.2% of participants across doses achieved 1-stage or greater fibrosis improvement without worsening of MASH versus 32.8% on placebo. The FDA granted breakthrough therapy designation for this indication. In a landmark head-to-head trial published in the New England Journal of Medicine (2025), tirzepatide was shown to be superior to semaglutide with respect to body weight reduction: the mean percent change in weight at week 72 was −20.2% with tirzepatide versus −13.7% with semaglutide, with tirzepatide also producing greater waist circumference reductions. The SURMOUNT trial series showed average weight loss of 20–25% of body weight in some cohorts. In the Phase 3 SURMOUNT-OSA trial, tirzepatide demonstrated a reduction of 25.3 to 29.3 events per hour in apnea-hypopnea index versus approximately 5 with placebo, alongside 17–20% body weight reduction — establishing a potential role in treating obesity-related obstructive sleep apnea. Tirzepatide is also in clinical trials for autoimmune conditions in adults with obesity — notably, Phase 3 trials combining tirzepatide with ixekizumab (Taltz) for plaque psoriasis and psoriatic arthritis in patients with obesity are expected to complete in the first half of 2026. Mounjaro is under FDA review for a new indication to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, with a decision expected in early-to-mid 2026. Tirzepatide monotherapy is also in clinical trials for type 1 diabetes (estimated completion 2027). The Phase 3 SUMMIT trial demonstrated that tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity over a median follow-up of approximately 2 years. Participants showed significant improvements in physical function, exercise tolerance, weight loss, and reduced systemic inflammation. While tirzepatide is not yet FDA-approved for HFpEF, these results position it as a potential first incretin therapy for obesity-related heart failure, with regulatory submission anticipated. A May 2026 meta-analysis of over 90,000 participants across multiple GLP-1 RA clinical trials confirmed that the GLP-1 receptor agonist class — including both semaglutide and tirzepatide — significantly reduces cardiovascular events including heart attacks, strokes, and heart failure hospitalization, further reinforcing the cardiometabolic benefits of incretin-based therapies. The Medicare GLP-1 Bridge program, launching July 1, 2026, covers Zepbound (KwikPen) for eligible Medicare Part D beneficiaries at a $50/month copayment — representing a major access expansion for one of the most effective obesity treatments available. The program runs through December 31, 2027, and is administered outside the standard Part D benefit, meaning copayments remain flat at $50 regardless of benefit phase. Alongside Foundayo and Wegovy, Zepbound is one of only three medications designated by CMS for the bridge program. Also known as: Mounjaro, Zepbound ## Regulatory Status FDA-Approved (T2D, obesity, MASH) FDA-approved as Mounjaro for type 2 diabetes (May 2022), as Zepbound for chronic weight management (November 2023), and for MASH with moderate-to-advanced fibrosis (early 2026). 73.3% of patients taking 15 mg achieved MASH resolution at 52 weeks in SYNERGY-NASH. SUMMIT trial for HFpEF with obesity submission anticipated. Effective: 2026 View FDA Source (https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-was-superior-placebo-mash-resolution-and-more) ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 3 (SURMOUNT) | Dual GIP/GLP-1 agonist | Average weight loss of 20-25% of body weight | Source: https://pubmed.ncbi.nlm.nih.gov/35658024/ | | Phase 3 (SURMOUNT-5) | Tirzepatide vs semaglutide head-to-head | Statistically superior weight loss vs semaglutide 2.4mg | Source: https://pubmed.ncbi.nlm.nih.gov/ | | Phase 3 (SURMOUNT-OSA) | Tirzepatide in obesity-related OSA | 25.3–29.3 AHI reduction vs ~5 placebo; 17–20% weight loss | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2404881 | | Phase 3 (NEJM 2025) | Tirzepatide vs semaglutide head-to-head, 72 weeks | −20.2% weight loss (tirzepatide) vs −13.7% (semaglutide); superior waist circumference reduction | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2416394 | | Phase 2 (SYNERGY-NASH) | Tirzepatide 5/10/15 mg vs placebo in MASH with fibrosis F2-F3, 52 weeks | 73.3% MASH resolution at 15 mg vs 13.2% placebo; 54.2% achieved ≥1-stage fibrosis improvement without worsening of MASH; led to FDA breakthrough therapy designation and 2026 MASH approval | Source: https://www.nejm.org/doi/abs/10.1056/NEJMoa2401943 | | Phase 3 (SUMMIT) | Tirzepatide in HFpEF with obesity (n=731), median ~2 years follow-up | 38% reduction in cardiovascular death or worsening heart failure; improved exercise tolerance and physical function; significant weight loss and reduced inflammation | Source: https://www.nature.com/articles/s41591-024-03374-z | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Researching Tirzepatide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=tirzepatide) ## Safety & Cautions - FDA-approved prescription medication requiring medical supervision - Common side effects include nausea, diarrhea, and decreased appetite - Contraindicated in patients with personal/family history of medullary thyroid carcinoma - Not for use with other GLP-1 receptor agonists - On May 1, 2026, the FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B Bulks List. Public comment period closes June 29, 2026. - Medicare GLP-1 Bridge launches July 1, 2026: eligible Part D beneficiaries can access Zepbound (KwikPen) at $50/month through December 31, 2027 ## Comparisons See how Tirzepatide compares to related peptides: Tirzepatide vs Cagrilintide: https://peptrackerpro.com/compare/tirzepatide-vs-cagrilintide Tirzepatide vs CagriSema: https://peptrackerpro.com/compare/tirzepatide-vs-cagrisema Tirzepatide vs CT-388: https://peptrackerpro.com/compare/tirzepatide-vs-ct-388 Tirzepatide vs Efocipegtrutide: https://peptrackerpro.com/compare/tirzepatide-vs-efocipegtrutide Tirzepatide vs Efpeglenatide: https://peptrackerpro.com/compare/tirzepatide-vs-efpeglenatide Tirzepatide vs Efruxifermin: https://peptrackerpro.com/compare/tirzepatide-vs-efruxifermin Tirzepatide vs Glepaglutide: https://peptrackerpro.com/compare/tirzepatide-vs-glepaglutide Tirzepatide vs Insulin Efsitora Alfa: https://peptrackerpro.com/compare/tirzepatide-vs-insulin-efsitora-alfa Tirzepatide vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/tirzepatide-vs-maridebart-cafraglutide Tirzepatide vs MariTide: https://peptrackerpro.com/compare/tirzepatide-vs-maritide Tirzepatide vs Mazdutide: https://peptrackerpro.com/compare/tirzepatide-vs-mazdutide Tirzepatide vs NA-931 (Bioglutide): https://peptrackerpro.com/compare/tirzepatide-vs-na-931 Tirzepatide vs Pegozafermin: https://peptrackerpro.com/compare/tirzepatide-vs-pegozafermin Tirzepatide vs Retatrutide: https://peptrackerpro.com/compare/tirzepatide-vs-retatrutide Tirzepatide vs Ribupatide: https://peptrackerpro.com/compare/tirzepatide-vs-ribupatide Tirzepatide vs Semaglutide: https://peptrackerpro.com/compare/tirzepatide-vs-semaglutide Tirzepatide vs Survodutide: https://peptrackerpro.com/compare/tirzepatide-vs-survodutide Tirzepatide vs UBT251: https://peptrackerpro.com/compare/tirzepatide-vs-ubt251 Tirzepatide vs WVE-007: https://peptrackerpro.com/compare/tirzepatide-vs-wve-007 Tirzepatide vs ARO-INHBE: https://peptrackerpro.com/compare/tirzepatide-vs-aro-inhbe Tirzepatide vs HRS9531 (KAI-9531): https://peptrackerpro.com/compare/tirzepatide-vs-hrs9531 ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Jastreboff AM. et al. — Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 PubMed (https://pubmed.ncbi.nlm.nih.gov/35658024/) 2. [2] Genetic predictors of GLP1 receptor agonist weight loss and side effects — Nature 2026 PubMed (https://www.nature.com/articles/s41586-026-10330-z) 3. [3] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — NEJM 2025 PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2416394) 4. [4] FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — FDA. May 2026 PubMed (https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list) 5. [5] Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis — NEJM 2024 PubMed (https://www.nejm.org/doi/abs/10.1056/NEJMoa2401943) 6. [6] Eli Lilly — SYNERGY-NASH Phase 2 results: MASH resolution and fibrosis improvement PubMed (https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-was-superior-placebo-mash-resolution-and-more) 7. [7] SUMMIT Trial -- Effects of tirzepatide on heart failure with preserved ejection fraction and obesity. Nature Medicine, 2024 PubMed (https://www.nature.com/articles/s41591-024-03374-z) 8. [8] CMS — Medicare GLP-1 Bridge: $50/month Zepbound coverage for Medicare Part D beneficiaries beginning July 1, 2026 PubMed (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge) ### Keep researching in the app - Log Tirzepatide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=tirzepatide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrisema \+ Compare: https://peptrackerpro.com/compare?select=cagrisema Track in App: https://app.peptrackerpro.com/?add=cagrisema ### CT-388 Medium Evidence An investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/ct-388 \+ Compare: https://peptrackerpro.com/compare?select=ct-388 Track in App: https://app.peptrackerpro.com/?add=ct-388 ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. Liver Health: https://peptrackerpro.com/benefits/liver-health Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/efocipegtrutide \+ Compare: https://peptrackerpro.com/compare?select=efocipegtrutide Track in App: https://app.peptrackerpro.com/?add=efocipegtrutide ### Efpeglenatide High Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health View Details: https://peptrackerpro.com/peptides/efpeglenatide \+ Compare: https://peptrackerpro.com/compare?select=efpeglenatide Track in App: https://app.peptrackerpro.com/?add=efpeglenatide ### Efruxifermin Medium Evidence Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026). Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/efruxifermin \+ Compare: https://peptrackerpro.com/compare?select=efruxifermin Track in App: https://app.peptrackerpro.com/?add=efruxifermin ### Glepaglutide Medium Evidence A long-acting glucagon-like peptide-2 (GLP-2) analog given by once- or twice-weekly subcutaneous injection that helps the gut absorb more nutrients in short bowel syndrome, reducing dependence on IV (parenteral) nutrition. Gut Health: https://peptrackerpro.com/benefits/gut-health View Details: https://peptrackerpro.com/peptides/glepaglutide \+ Compare: https://peptrackerpro.com/compare?select=glepaglutide Track in App: https://app.peptrackerpro.com/?add=glepaglutide ### Insulin Efsitora Alfa High Evidence A once-weekly basal insulin engineered as a single-chain insulin analog fused to an antibody (IgG2) Fc fragment, giving it a roughly 17-day half-life so a single subcutaneous injection covers a full week. Developed by Eli Lilly (code LY3209590, also called basal insulin Fc or BIF), efsitora is designed to replace daily long-acting insulin with a flat, ultra-stable weekly profile. In the large Phase 3 QWINT program it matched daily insulins glargine and degludec on A1C in type 2 diabetes, and in insulin-naive patients its simplified fixed-dose titration cut the number of dose adjustments dramatically while keeping hypoglycemia low. In type 1 diabetes (QWINT-5) it was non-inferior on A1C but showed a higher rate of severe hypoglycemia, a key safety caveat. As of mid-2026 efsitora is under FDA review for type 2 diabetes (a decision expected in the third quarter of 2026) and would compete directly with Novo Nordisk's once-weekly insulin icodec (Awiqli). Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Hormone Support: https://peptrackerpro.com/benefits/hormone-support View Details: https://peptrackerpro.com/peptides/insulin-efsitora-alfa \+ Compare: https://peptrackerpro.com/compare?select=insulin-efsitora-alfa Track in App: https://app.peptrackerpro.com/?add=insulin-efsitora-alfa ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. View Details: https://peptrackerpro.com/peptides/maritide \+ Compare: https://peptrackerpro.com/compare?select=maritide Track in App: https://app.peptrackerpro.com/?add=maritide ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. View Details: https://peptrackerpro.com/peptides/mazdutide \+ Compare: https://peptrackerpro.com/compare?select=mazdutide Track in App: https://app.peptrackerpro.com/?add=mazdutide ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/na-931 \+ Compare: https://peptrackerpro.com/compare?select=na-931 Track in App: https://app.peptrackerpro.com/?add=na-931 ### Pegozafermin Medium Evidence Pegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG. View Details: https://peptrackerpro.com/peptides/pegozafermin \+ Compare: https://peptrackerpro.com/compare?select=pegozafermin Track in App: https://app.peptrackerpro.com/?add=pegozafermin ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Ribupatide Medium Evidence A once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO. View Details: https://peptrackerpro.com/peptides/ribupatide \+ Compare: https://peptrackerpro.com/compare?select=ribupatide Track in App: https://app.peptrackerpro.com/?add=ribupatide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/ubt251 \+ Compare: https://peptrackerpro.com/compare?select=ubt251 Track in App: https://app.peptrackerpro.com/?add=ubt251 ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/wve-007 \+ Compare: https://peptrackerpro.com/compare?select=wve-007 Track in App: https://app.peptrackerpro.com/?add=wve-007 ### ARO-INHBE Low Evidence An investigational RNA-interference (RNAi) therapeutic from Arrowhead Pharmaceuticals designed to treat obesity by silencing a fat-storage gene in the liver. ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) that reduces hepatic expression of the INHBE gene and its secreted product, the hepatokine Activin E. INHBE is a genetically validated target: people who naturally carry rare loss-of-function variants in INHBE have a healthier (less abdominal) fat distribution and a lower risk of type 2 diabetes, suggesting that lowering Activin E with a drug could reproduce that protective metabolic profile. In an ongoing Phase 1/2a trial (AROINHBE-1001, NCT06700538), a single subcutaneous dose reduced serum Activin E by up to about 94%, and monotherapy reduced visceral fat by roughly 10-16% while modestly increasing lean tissue. Most strikingly, when added to the incretin drug tirzepatide in obese patients with type 2 diabetes, ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8% at week 16) and roughly tripled reductions in visceral, total, and liver fat versus tirzepatide alone. These are small, early, interim results (as few as 3-4 participants per combination arm) - not proof of durable or long-term benefit. ARO-INHBE is investigational, is not approved anywhere, and is not a supplement or research chemical; it is studied only in clinical trials. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/aro-inhbe \+ Compare: https://peptrackerpro.com/compare?select=aro-inhbe Track in App: https://app.peptrackerpro.com/?add=aro-inhbe ### HRS9531 (KAI-9531) Medium Evidence An investigational once-weekly injectable dual GLP-1/GIP receptor agonist - the same peptide class as tirzepatide (Zepbound/Mounjaro) - developed by China's Jiangsu Hengrui Pharmaceuticals as HRS9531 and licensed to U.S.-based Kailera Therapeutics, which is developing it globally (outside Greater China) as KAI-9531. In the pivotal 48-week Phase 3 GEMINI-1 trial in China (NCT06396429; 567 adults with obesity or overweight without diabetes), once-weekly HRS9531 produced mean weight loss of about 17.4-19.2% at the 4 mg and 6 mg doses (per-protocol/hypothetical estimand) versus roughly 1.4% for placebo, with about 44% of 6 mg patients losing at least 20% of body weight and broad improvements in blood pressure, lipids, insulin resistance, and inflammation (hsCRP). An earlier Phase 2 trial reported about 23.6% mean weight loss at the higher 8 mg dose by week 36 with no plateau. Hengrui has submitted a marketing application to China's NMPA for chronic weight management, and Kailera began a global Phase 3 program (KAI-9531) evaluating higher maintenance doses (8 mg and 10 mg) and longer treatment by late 2025. HRS9531/KAI-9531 is investigational, is not approved outside of any regulatory review in China, and is not a supplement or research chemical; it is studied only in clinical trials. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/hrs9531 \+ Compare: https://peptrackerpro.com/compare?select=hrs9531 Track in App: https://app.peptrackerpro.com/?add=hrs9531 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Tirzepatide", "description": "A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.", "url": "https://peptrackerpro.com/peptides/tirzepatide", "lastReviewed": "2026-06-30", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Tirzepatide", "item": "https://peptrackerpro.com/peptides/tirzepatide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching FDA-approved weight management options?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a research peptide studied in preclinical models. A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis." } }, { "@type": "Question", "name": "Those comparing GLP-1 receptor agonists?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a research peptide studied in preclinical models. A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis." } }, { "@type": "Question", "name": "Individuals exploring dual incretin therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a research peptide studied in preclinical models. A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis." } } ] } ] ```